but it wouldn't be the holidays without Blueprint Ventures' Gary Snoman.
For those unfamiliar with Gary, his earlier work.
Wednesday, 19 December 2007
Subscribe to:
Post Comments (Atom)
Popular Posts
-
In his talk introducing the top-10 most licensable oncology drugs at the Therapeutic Alliances conference last Friday, Ben Bonifant of Campb... -
So Synta’s PR firm were pushing today’s deal with GlaxoSmithKline at us as “one of the biggest product deals this year” and indeed “among t... -
China has been preparing feverishly for the Beijing Olympics for years to showcase its new world position and economic power. China's co... -
Many analysts have questioned the potential of Pfizer’s inhaled insulin, Exubera . Nonetheless, it was more than surprising to see the comme... -
Merck and Schering-Plough put out a release a few minutes ago responding to critics of ENHANCE and the trial results' fallout: WHITEHOU...
-
Active surveillance and data mining are scary, right? It is common wisdom that these tools in the hands of academics, health plans and regul... -
Addex Pharma today took a step up the dealmaking ladder , partnering its pre-IND positive allosteric modulator ADX63365 and back-up compound... -
“Increased patient safety” drove Pfizer’s recent deal with UK wholesaler Alliance UniChem, according to the partners. But no one’s buying th...
-
As a small follow up to our post last week on Sofinnova Partners' hiring an Asia-focused professional, VentureWire Lifescience reported... -
Admittedly, it's been a quiet week for biz dev in pharma land. The big news has been clinical. On the positive side, the diabetes triumv...
0 comments:
Post a Comment